# Review 5: Tone & Positioning

**Reviewer role:** Tone, rhetoric, strategic positioning, and confidentiality audit
**Paper:** "The Blind Spots of Agentic Drug Discovery"
**Date:** 2026-02-06

---

## A) Tone Consistency

### Overall Assessment: Strong, with minor lapses

The paper achieves the target "authoritative but accessible" tone of a Nature perspective piece for the vast majority of its length. The writing is precise, concrete, and avoids both academic dryness and blog-level casualness. It reads as a serious, grounded critique from someone who has done the work.

### Sections that work best tonally

- **Introduction (Section 1):** The opening paragraph efficiently establishes what exists, then pivots cleanly to what is missing. The line "The enthusiasm is warranted, but it is also narrowly scoped" exemplifies the constructive tone: acknowledging progress, then identifying limits. This is exactly the right register.

- **Section 3 (Multi-Paradigm):** The distinction between "multi-agent" and "multi-paradigm" is stated with clarity and conviction. The framing is precise, not adversarial. "This distinction matters" is a strong, clean sentence that demonstrates authority without aggression.

- **Section 7 (Wishlist):** The concrete use cases ground the recommendations effectively. The Input/Workflow/Output/Human-decisions structure is practical and reader-friendly.

### Sections with tonal concerns

- **Section 2 (Small Molecule Bias), paragraph 2:** The line "Practitioners encounter immediate friction" edges toward complaint-register. While factually accurate, the word "friction" combined with the catalog of failures ("cannot encode," "no analog," "unreliable scores," "meaningless," "awkward") accumulates into a litany. Consider softening one or two items or reframing the final sentence more constructively, e.g., noting what alternative representations would be needed rather than dwelling on what does not work.

- **Section 5 (Small Biotech), final paragraph:** "Agents are optimized for AstraZeneca. The biotech sector where significant innovation happens is left behind." The second sentence risks reading as adversarial toward AstraZeneca specifically and as an unsupported claim ("significant innovation happens" in biotech). This could be softened to something like: "Agents designed for large pharma contexts leave the biotech sector underserved." The current phrasing may alienate readers at large pharma who are otherwise the natural audience for these recommendations.

- **Section 4 (Multi-Paradigm), final paragraph:** "not LLMs chatting" is slightly too casual for the venue. This phrase appears twice in the paper (once in the introduction road-map and once at the end of Section 4). While it is vivid and memorable, it is dismissive of the multi-agent paradigm. A phrase like "not LLM-to-LLM delegation" would convey the same point without the sarcasm.

### Tonal consistency verdict

The paper is 90% on target. The remaining 10% consists of moments where frustration bleeds through and the tone shifts from "constructive diagnosis" to "practitioner venting." These are minor and easily fixed, but they matter for venue credibility at Nature Machine Intelligence or Drug Discovery Today.

---

## B) Practitioner Credibility

### Overall Assessment: Highly convincing

The practitioner voice is one of the paper's strongest assets. The author establishes credibility through specificity of problems encountered, not through namedropping or institutional affiliation.

### What works well

1. **Concrete, anonymized workflow descriptions:** Passages like "training a multi-task neural network predicting peptide bioactivity across four endpoints using 300 sequences" (Section 4) are specific enough to be credible and general enough to be safe. The reader can tell this person has actually done this work.

2. **Multi-paradigm range:** The paper draws on ML, RL, computer vision, RNA-seq, behavioral phenotyping, and dose-response modeling. This breadth is unusual and convincing. It would be very difficult to fake.

3. **Practical pain points:** Details like "5-fold cross-validation leaves only 20 examples for evaluation" (Section 5) demonstrate working familiarity with the actual constraints. These are the observations of someone who has tried and found the limits, not someone speculating.

4. **Workflow sequences:** The active learning description in Section 5 ("Round one: 20 diverse peptides. Round two: 15 targeting high uncertainty. Round three: exploiting predicted best candidates") reads as genuine practitioner experience. It is specific enough to be informative yet generic enough to apply to many settings.

### Minor credibility concerns

1. **Missing practitioner positioning statement:** The introduction mentions "years of computational projects" but never explicitly says "I" or establishes the author's role in first person. The abstract says "Drawing on experience with computational drug discovery projects at a small biotech specializing in therapeutic peptides." This is good but somewhat passive. Consider adding one sentence in the introduction that directly states the author's vantage point, e.g., "The author has led computational drug discovery across these paradigms at a small biotech, serving as both drug designer and AI practitioner."

2. **Project count removed:** The CLAUDE.md mentions "14+ projects" as a credibility anchor, but this number does not appear in the manuscript. Restoring a version of this claim (e.g., "Drawing on over a dozen computational projects spanning...") would strengthen the authority without revealing specifics.

---

## C) Confidentiality Audit

### PASS: No direct leaks detected

A systematic search for all restricted terms found zero matches:
- StemRIM: not present
- TRIM2/3/4/5, SRA-9, SR-A9, Redasemtide: not present
- Seq2Risk, PEM, LEMUR: not present
- LRP1 (in connection to author's work): not present
- Tamai: not present
- "50 employees," "Japanese," "regenerative medicine" (in connection to the author): not present in sections

### Indirect identification risks (low but worth noting)

1. **"Traumatic brain injury" specificity:** TBI is mentioned explicitly in Sections 1, 2, 3, and implicitly throughout. The combination of (a) small biotech, (b) therapeutic peptides, (c) TBI indication, (d) behavioral phenotyping, and (e) a sole computational scientist is a narrow intersection. Someone in the Japanese biopharma space who knows the field could potentially narrow this down. However, this combination of details is spread across different sections and never appears in a single sentence, which reduces the risk. The paper also discusses TBI as a general example ("traumatic brain injury models"), not as the author's sole focus.

   **Risk level: Low-to-moderate.** The TBI references are important for grounding the argument. If the author is comfortable with potential identification by close colleagues (who likely already know about the work), this is acceptable. If stronger anonymity is desired, some TBI references could be generalized to "neurological injury models" or "CNS disorder models."

2. **"Beam walking" in Section 3:** The phrase "motor coordination via beam walking" is a specific behavioral assay. Combined with TBI and peptides, this further narrows identification. However, beam walking is a standard assay used across hundreds of TBI labs, so this alone is not identifying.

3. **"Bone formation quantification" in Section 4:** The reference to "bone formation quantification trained semantic segmentation models" is a specific project category from the CLAUDE.md list. It appears only once and in a list of paradigm examples, which is safe. However, if bone formation is a known area of the company's work, this could be mildly identifying.

4. **"Social bonding quantification" absence:** The manuscript correctly avoids mentioning "mouse togetherness" or "social bonding" from the CLAUDE.md. Behavioral phenotyping is discussed only in terms of DeepLabCut and generic pose estimation, which is safe.

### Confidentiality verdict

The manuscript passes the confidentiality audit. All restricted terms are absent. The indirect identification risk from the TBI + peptide + small biotech combination is inherent to writing a paper about the author's actual experience and cannot be fully eliminated without gutting the paper's credibility. The current level of abstraction is appropriate for the target venues.

---

## D) Framing: Complementary Counterpoint

### Overall Assessment: The framing works well but could be sharper in two places

The "complementary counterpoint" positioning is successfully established in the introduction. The paper does not read as adversarial. It acknowledges the contributions of existing systems (ChatInvent, ChemCrow, Coscientist) before identifying their limits. This is the right approach.

### What works

1. **The opening paragraph** names specific systems and their achievements before introducing gaps. This is generous and establishes credibility: the author knows what exists.

2. **Each gap section** begins by naming what current agents do (e.g., "ChemCrow includes RDKit" in Section 2) before explaining why it is insufficient. This consistent pattern reinforces the "building on, not tearing down" framing.

3. **The wishlist (Section 7)** is explicitly constructive. By ending with concrete design principles and use cases, the paper shifts from diagnosis to prescription.

### Where the framing could be stronger

1. **He et al. (ChatInvent) positioning:** The paper references ChatInvent multiple times (Sections 1, 4, 5, conclusion) as a case study of large-pharma agent design. The framing is fair but could be more explicitly generous. Consider adding a line like: "ChatInvent's 13-month deployment demonstrates that agentic systems can deliver value in production settings; the question is how to extend this success beyond its design context."

2. **Lakhan reference is underutilized:** Lakhan (2025) is cited once in the introduction but never meaningfully engaged. The CLAUDE.md positions this paper as responding to Lakhan's "cheerleading." A sentence or two in the conclusion contrasting the paper's specific, evidence-based recommendations with Lakhan's high-level advocacy would sharpen the positioning: "Calls for biopharma to embrace agentic AI [Lakhan 2025] are necessary but insufficient without addressing the architectural gaps that prevent adoption in most real-world settings."

3. **Seal et al. engagement:** The survey by Seal et al. is referenced but could be engaged more directly. A line like "Comprehensive surveys [Seal et al. 2025] map the landscape of existing tools but do not address gaps where tools do not yet exist" would make the complementary positioning explicit.

### Framing verdict

The paper succeeds as a complementary counterpoint. It will not be read as an attack. The suggestions above would sharpen the positioning against the three target papers without changing the fundamental approach.

---

## E) Call to Action

### Overall Assessment: Good structure, could be more specific

The three-audience call to action (researchers, practitioners, funders) is well-structured and covers the right stakeholders.

### Strengths

- Addressing three distinct audiences prevents the "so what?" problem
- The researcher call is actionable: "Move beyond tool-calling to multi-paradigm orchestration" is concrete
- The practitioner call appropriately asks for sharing anonymized problem formulations

### Weaknesses

1. **The researcher call could name specific deliverables:** Instead of "Build data-efficient, modality-aware systems," consider: "Develop benchmarks for peptide-aware agents, multi-paradigm workflow orchestration, and in vivo data integration. Current benchmarks (ChemToolAgent, BioPlanner) test text-based reasoning; the field needs benchmarks testing training, optimization, and multi-modal fusion."

2. **The funder call is vague:** "Support open infrastructure for PLMs, structural biology tools, reproducible datasets, and workflow orchestration" is a wish list, not a call to action. What specific funding mechanisms or initiatives would help? Something like: "Fund shared computational infrastructure accessible to resource-constrained biotechs, similar to how cloud computing credits programs have democratized access to GPU resources."

3. **Missing: a call to platform developers.** The paper critiques existing agent platforms but does not directly address their developers. A line like "For agent developers: Treat ML training, RL, and simulation as first-class orchestration primitives, not afterthoughts" would be well-targeted.

4. **The final paragraph** ("The past three years showed what is possible...") is strong and forward-looking. The closing line, "If not, adoption will remain limited," is appropriately measured rather than alarmist.

### Call to action verdict

The structure is sound. Specificity improvements would strengthen it, but the current version is adequate for the target venues.

---

## F) Formatting

### Emdashes

No emdashes (---, or the Unicode character) were found anywhere in the manuscript. The paper uses commas, semicolons, colons, and separate sentences throughout. This is consistent with the style guidelines.

### Other formatting observations

1. **Parenthetical ranges:** The paper consistently uses "to" rather than hyphens for ranges in text (e.g., "5 to 50 amino acids," "50 to 500 proprietary sequences"), which is clean and readable.

2. **Section numbering:** The sections are well-labeled with LaTeX cross-references. The roadmap at the end of the introduction correctly points to all five gap sections and the wishlist.

3. **Table formatting:** Tables 1, 2, and 3 are well-structured and informative. Table 3 (Practitioner's Wishlist Priority Matrix) is particularly effective at summarizing the paper's recommendations.

4. **Figure placement:** Figures are placed at the beginning of relevant sections, which is appropriate. The captions are descriptive and self-contained.

5. **Citation density:** Appropriate throughout. The paper cites specific systems when making claims about their capabilities and does not make unsupported statements about competitors.

### Formatting verdict

Clean and consistent. No issues found.

---

## G) Rhetorical Effectiveness

### Most persuasive sections (ranked)

1. **Section 3 (In Vivo to In Silico Bridge):** This is the paper's strongest section rhetorically. The concrete data types (behavioral videos, RNA-seq, clinical trajectories) make the gap visceral. Table 1 is an excellent visualization of what agents can and cannot process. The temporal modeling argument (days 1-3, 7-10, 28) is concrete and compelling. This section will resonate with anyone who has worked with animal data.

2. **Section 4 (Multi-Paradigm):** The "multi-agent vs. multi-paradigm" distinction is the paper's most novel conceptual contribution. The example of training a multi-task neural network on 300 sequences is perfectly calibrated: specific enough to be real, general enough to represent a class of problems. The argument that agents treat ML training as outside scope, while practitioners spend most of their time on it, is immediately convincing.

3. **Section 2 (Small Molecule Bias):** The peptide-specific challenges (conformational flexibility, protease degradation, aggregation) are well-articulated. The comparison with small-molecule tools is clear. The weakest part is the subsection on "What Peptide-Aware Agents Would Need," which reads more as a feature list than an argument. Consider adding a motivating example before the list.

### Least persuasive sections (ranked from weakest)

1. **Section 6 (Multi-Objective):** This section makes a valid point but is the least distinctive. Multi-objective optimization is a well-known challenge, and the argument that agents use weighted sums is not surprising. The Pareto frontier discussion is technically correct but reads as textbook material rather than practitioner insight. The section would benefit from a more vivid opening example and from emphasizing what is unique to the drug discovery context (regulatory risk tolerance, stage-dependent preferences) rather than the general multi-objective optimization problem.

2. **Section 5 (Small Biotech):** The resource constraints are real, but the argument occasionally reads as "we have less than AstraZeneca" without sufficient specificity about what agent features would help. The active learning paragraph is excellent and should be expanded. The batch-mode argument is practical but undersold. The section would be stronger if it led with the most compelling constraint (data scarcity and its consequences) rather than listing all constraints equally.

### Rhetorical patterns that work

- **Concrete then abstract:** The paper consistently presents a specific scenario, then generalizes. This grounds every claim in experience.
- **Naming existing systems:** By citing ChemCrow, ChatInvent, and Coscientist by name and explaining their capabilities, the paper shows familiarity and respect before identifying gaps.
- **Structured subsections:** Each gap section follows a consistent pattern (what exists, why it fails, what is needed), which builds cumulative credibility.

### Rhetorical patterns that could improve

- **Repetition of "agents cannot":** The phrase "agents cannot" or "no agent" appears frequently across all sections. While accurate, the repetition risks becoming monotonous. Varying the phrasing (e.g., "this remains outside agent scope," "no current system supports," "practitioners must handle this manually") would maintain the point without the drumbeat quality.
- **Missing antagonist framing in wishlist:** The wishlist (Section 7) presents positive recommendations but does not explicitly tie each principle back to the corresponding gap. Adding brief backward references (e.g., "Addressing the small-molecule bias [Section 2], agents must...") would strengthen the paper's structural coherence.

---

## Summary of Recommendations

### Critical (should fix before submission)

1. Soften "Agents are optimized for AstraZeneca" in Section 5 closing paragraph; the current phrasing is adversarial and may alienate target readers.
2. Replace "not LLMs chatting" (appears twice) with a less dismissive phrase.

### Important (would strengthen the paper)

3. Add one sentence in the introduction explicitly establishing the author's first-person practitioner vantage point.
4. Engage Lakhan (2025) and Seal et al. (2025) more explicitly in the conclusion to sharpen the complementary counterpoint positioning.
5. Add more specific deliverables to the call to action (benchmarks, funding mechanisms, platform features).
6. Vary the "agents cannot" phrasing to avoid repetition.
7. Strengthen Section 6 (Multi-Objective) with a more vivid opening that emphasizes what is unique to drug discovery rather than general optimization theory.

### Minor (polish)

8. Consider whether TBI specificity is acceptable given indirect identification risk. If not, generalize some references to "neurological injury models."
9. Add backward references from wishlist principles to their corresponding gap sections.
10. Restore a version of the "14+ projects" claim to the introduction for credibility anchoring.

### Confidentiality status: PASS

No restricted terms found. Indirect identification risk is low-to-moderate and inherent to the paper's approach.
